XTalks

NOVEMBER 12, 2024

Pneumonia is a lung infection that can be caused by viruses, bacteria or fungi and can result in millions of hospitalizations and deaths annually. For example, recent clinical trials and regulatory approvals for RSV vaccines are notable milestones that indicate advancements in preventing viral pneumonia in both children and elderly adults.

Bacteria 110

Bacteria Life Science Vaccine Vaccination 110

Medical Xpress

APRIL 20, 2023

Gut bacteria that break down a sugar called fucose could be dampening our immune response to the COVID-19 mRNA vaccine, according to a study led by researchers from the Okinawa Institute of Science and Technology (OIST).

Immune Response 111

Immune Response Bacteria Vaccine Vaccination 111

Medical Xpress

NOVEMBER 25, 2022

A team of researchers at Duke University has developed a vaccine against uropathogenic E. coli (UPEC), the type of bacteria that cause urinary tract infections (UTIs) in humans.

Bacteria 98

Bacteria Vaccine Vaccination Development 98

Pharmaceutical Technology

OCTOBER 6, 2022

from the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). Leveraging its outer membrane vesicles (OMV) platform technology, Intravacc will develop the vaccine.

Vaccine 147

Vaccine Vaccination Development Bacterium 147

Pharmaceutical Technology

OCTOBER 28, 2022

On 24 October, American vaccine developer Vaxcyte shared positive topline data from a Phase I/II study of its multivalent conjugate pneumococcal vaccine VAX-24 , bringing the 24-valent pneumococcal jab one step closer to market. This is in addition to its long-available pneumococcal polysaccharide vaccine PPSV23.

Vaccine 162

Vaccine Vaccination Marketing Bacteria 162

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Coronavirus vaccine components. The vaccine also contains other inactive ingredients such as cholesterol.

Vaccine 130

Vaccine Vaccination Containment Immune Response 130

pharmaphorum

DECEMBER 4, 2020

Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets.

Vaccine 119

Vaccine Vaccination Bacterium Protein 119

Scienmag

JUNE 2, 2022

An investigation into the evolution of Salmonella bacteria infecting Brazilian poultry shows that the introduction of a Salmonella vaccine, combined with increasing antibiotic usage by Brazilian farmers, has led to the rise of strains that are more antibiotic-resistant, but less likely to cause disease in humans.

Bacteria 78

Bacteria Vaccine Vaccination 78

Pharma Times

DECEMBER 20, 2023

The Novo Nordisk Foundation has committed $260m to establish a new state-of-the-art research and vaccine development initiative to help combat deadly airborne infections. The initiative aims to create new or improved vaccines for deadly respiratory diseases, including tuberculosis (TB) and influenza. million deaths every year.

Vaccine 110

Vaccine Vaccination Immune Response Bacteria 110

Scienmag

NOVEMBER 9, 2020

— Similar to bacteria evolving resistance to antibiotics, viruses can evolve resistance to vaccines, and the evolution of SARS-CoV-2 could undermine the effectiveness of vaccines that are currently under development, according to a paper published November 9 in the open-access journal PLOS […]. UNIVERSITY PARK, Pa.

Vaccine 98

Vaccine Vaccination Bacteria Development 98

XTalks

JUNE 21, 2024

The US Food and Drug Administration (FDA) has green-lighted the first pneumonia vaccine specifically designed for adults 50 years of age and older. These numbers do not reflect the efficacies of the vaccines, which have not been compared head-to-head in any trial yet.

FDA Approval 108

FDA Approval Vaccine Vaccination Life Science 108

Scienmag

JULY 7, 2021

Researchers have produced vaccine-like immune responses to a dangerous bacterium by colonizing 26 healthy volunteers with a related, but harmless, commensal bacterial species.

Bacteria 75

Bacteria Bacterium Immune Response Vaccine 75

pharmaphorum

SEPTEMBER 28, 2021

Prospects for Valneva’s COVID-19 vaccine are up in the air, but another candidate partnered with Pfizer looks increasingly like it could fill the void of an effective shot for Lyme disease. billion contract to supply up to 100 million doses of its COVID-19 vaccine VLA2001.

Vaccine 105

Vaccine Vaccination Bacteria Protein 105

Pharmaceutical Technology

AUGUST 1, 2022

Since 2020, government agencies have provided funding for expensive late-stage vaccine development and the expansion of manufacturing capacity, as well as other key pharmaceutical activities. The shift from private to public funding enabled more rapid development of Covid-19 drugs and vaccines.

Vaccination 234

Vaccination Vaccine Bacteria Life Science 234

AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 22, 2022

The Indian Institute of Science (IISc), Centre for BioSystems Science and Engineering, has designed a new method to deliver a vaccine candidate for tuberculosis (TB). The research involves using spherical vesicles secreted by bacteria coated on gold nanoparticles which can then be delivered to the immune cells.

Vaccine 100

Vaccine Vaccination Research Bacteria 100

XTalks

AUGUST 17, 2022

August is National Immunization Awareness Month (NIAM), which is marked to help raise awareness about the importance of vaccines in the protection of public health. One of the themes of this year’s National Immunization Awareness Month is “vaccines work.” Vaccination Awareness from the FDA.

Vaccine 98

Vaccine Vaccination Bacteria Development 98

Scienmag

JULY 8, 2021

A new vaccine technology combining capture of bacterial pathogens with effective immune-reprogramming biomaterials could be applied to a broad spectrum of infectious diseases Credit: Wyss Institute at Harvard University.

Vaccine 98

Vaccine Vaccination Bacteria Drugs 98

XTalks

JULY 28, 2021

Merck has scored US Food and Drug Administration (FDA) approval for its next-generation pneumonia vaccine Vaxneuvance that covers 15 different strains of the pneumococcal bacteria that causes the infection. Both next-gen shots offer enhanced protection against bacteria that can cause pneumonia, blood infections and meningitis.

FDA Approval 89

FDA Approval Vaccine Vaccination Immune Response 89

XTalks

JULY 25, 2023

Emergent BioSolutions, a multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland, has achieved a significant milestone with the approval of its Cyfendus (Anthrax Vaccine Adsorbed, Adjuvanted) vaccine by the US Food and Drug Administration (FDA). anthracis , primarily affecting livestock and wild game.

FDA Approval 98

FDA Approval Vaccine Vaccination Antibody 98

Scienmag

OCTOBER 2, 2020

Credit: Virginia Tech Renowned tick immunobiologist Utpal Pal wants to ad apt the rabies vaccination platform to produce antibodies that can protect against Borrelia burgdorferi, the bacteria responsible for Lyme disease. The intention is to apply this work to other tick-borne diseases in the future.

Vaccine 88

Vaccine Vaccination Bacteria Development 88

XTalks

DECEMBER 23, 2024

Meanwhile, expanded malaria vaccine access in 17 countries offers hope, poised to save tens of thousands of lives annually. Preparing for these events involves strengthening early detection systems, expanding vaccine distribution networks and addressing critical public health gaps. AI continues to play a growing role.

Vaccine 52

Vaccine Vaccination Containment Bacteria 52

NPR Health - Shots

NOVEMBER 9, 2022

Several crises in the country — including political instability, COVID and financial collapse — have created deteriorating conditions that have allowed the bacteria to spread. Image credit: Ari Daniel/NPR)

Bacteria 98

Bacteria Vaccination Vaccine 98

Scienmag

MAY 9, 2021

Researchers have successfully developed a new Strep A human challenge model, paving the way to test vaccines against the common deadly bacteria that causes sore throats, scarlet fever and skin sores.

Bacteria 49

Bacteria Vaccine Vaccination Research 49

Pharmaceutical Technology

DECEMBER 21, 2023

This innovative composition induces a protective immune response against Group A Streptococcus (GAS) bacteria, offering potential targets for vaccine development. Discover a groundbreaking immunogenic composition patent that combines GAS polypeptide antigens and polypeptide-polysaccharide conjugates.

Immune Response 100

Immune Response Bacteria Vaccine Vaccination 100

Delveinsight

JULY 27, 2021

GlaxoSmithKline announced the US Food and Drug Administration approval for its vaccine, Shingrix (Zoster Vaccine Recombinant, Adjuvanted) under trials in 18+ adults who are vulnerable or at an increased risk to Shingles , which is already commercialized for patient group aged 50 and above.

Vaccine 96

Vaccine Vaccination Trials Manufacturing 96

pharmaphorum

NOVEMBER 25, 2020

AstraZeneca’s research chief has said that the more effective dosing regimen of its coronavirus vaccine was discovered by accident. According to Reuters , the AstraZeneca development team made a minor mistake that made them realise they could significantly boost the success rate of the vaccine, codenamed AZD1222.

Vaccine 119

Vaccine Vaccination Bacteria RNA 119

Medical Xpress

DECEMBER 23, 2022

Formed in response to infection and vaccination, these microscopic training grounds allow B cells to perfect the antibodies they deploy against specific viruses and bacteria.

Bacteria 104

Bacteria Antibody Manufacturing Vaccination 104

Medical Xpress

MARCH 1, 2025

Often the perpetrators are viruses and bacteria you've conquered; others are undercover agents like vaccines given to trigger protective immune responses or even red herrings in the form of healthy tissue caught in immunological crossfire.

Immune Response 93

Immune Response Bacteria Vaccination Vaccine 93

Pfizer

FEBRUARY 16, 2023

who had been enrolled in the Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524) Phase 3 clinical study. The study is investigating the efficacy, safety and immunogenicity of an investigational Lyme disease vaccine candidate, VLA15. OspA is a surface protein expressed by the bacteria when present in a tick.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccine Vaccination 76

STAT News

SEPTEMBER 30, 2022

The shortlist includes researchers who elucidated how cells make energy, those who discovered the chemical chatter of bacteria, many of the brilliant minds who shepherded us into the “ era of the genome ,” and most prominently, the pioneers behind the mRNA Covid vaccines. Read the rest…

Bacteria 124

Bacteria Genome Genomics Vaccination 124

Scienmag

JUNE 10, 2022

Researchers have known for some time that maternal breast milk provides critical nutrients for newborns, and antibodies from mothers vaccinated against a specific disease-causing bacterium or virus can be transferred via breast milk to babies.

Antibody 72

Antibody Bacteria Bacterium Vaccination 72

XTalks

OCTOBER 14, 2022

Boostrix is the first vaccine in the US indicated for the protection of newborns under two months of age from pertussis. The vaccine is a Tdap vaccine (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) that can be administered during the third trimester of pregnancy.

FDA Approval 98

FDA Approval Vaccine Vaccination Protein 98

BioSpace

OCTOBER 19, 2020

In a challenge trial, people are given a vaccine then intentionally dosed with the virus or bacteria that causes the disease.

Bacteria 74

Bacteria Trials Vaccine Vaccination 74

XTalks

FEBRUARY 11, 2021

Amidst growing global shortages of COVID-19 vaccine supplies, inaugural (by way of authorizations/approvals) COVID-19 vaccine maker Pfizer is addressing the issue by working to cut the manufacturing time of its vaccine by almost half. Related: Pharma Rivals Step Up to Assist with COVID-19 Vaccine Production.

Manufacturing 52

Manufacturing Vaccine Vaccination DNA 52

XTalks

DECEMBER 17, 2021

The year continued to be dominated by COVID-19, and the second year of the pandemic was all about vaccines. And while over 8 billion doses of vaccines have been administered worldwide, billions more are still needed. And while over 8 billion doses of vaccines have been administered worldwide, billions more are still needed.

Life Science 98

Life Science Vaccine Vaccination Trials 98

pharmaphorum

MAY 31, 2022

billion takeover of US biotech Affinivax, buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated by Pfizer’s Prevnar franchise. The post GSK bolsters vaccines division with $3.3bn swoop on Affinivax appeared first on. GlaxoSmithKline has agreed a $3.3

Vaccine 52

Vaccine Vaccination Bacterium Sales 52

pharmaphorum

JUNE 20, 2022

stake in French vaccines developer Valneva at a cost of €90.5 VLA15 is the only vaccine for the tick-borne infection in clinical development, and is due to start a phase 3 trials programme in the third quarter of this year, said Pfizer. Pfizer has acquired an 8.1% The UK has approved the COVID shot – but backed out of a $1.5

Vaccination 98

Vaccination Vaccine Licensing Licensing 98